A recent executive order signed by President Trump has directed his administration to expedite the review of psychedelic drugs, primarily focusing on their potential for treating serious mental health conditions. This federal initiative marks a significant turning point in the United States’ approach to psychedelics, substances long classified under the most restrictive federal categories. While the order specifically targets mental health applications, the broader scientific community has noted the promise of compounds like psilocybin – the psychoactive component of "magic mushrooms" – in diverse therapeutic areas, including chronic pain management. This governmental push comes amid an unprecedented surge in public interest and use of psilocybin, creating a complex landscape where scientific understanding and regulatory frameworks are struggling to keep pace with evolving societal trends.
The burgeoning interest in psilocybin is emblematic of a broader "renaissance" in psychedelic science, a field that was largely dormant for decades due to stringent federal prohibitions. Once relegated to the counterculture, psilocybin is now at the forefront of medical research, with numerous studies exploring its efficacy for conditions ranging from depression and anxiety to PTSD and substance use disorders. Public engagement with these substances is not merely academic; data indicates a dramatic increase in psilocybin use across various demographics. One study revealed a 44% increase in psilocybin use among adults aged 18-29 between 2019 and 2023, while those over 30 saw an astonishing 188% rise in the same period. This translates to over 5 million adults using psilocybin in 2023 alone. More recent findings, published in early 2026, suggest this upward trend is accelerating, with approximately 11 million adults in the United States reporting psilocybin use in the preceding year. These figures underscore a rapidly expanding consumer base, many of whom are navigating an unregulated market with limited reliable information.
A Parallel with Cannabis: Market Outpaces Regulation
The trajectory of psilocybin’s re-emergence bears striking resemblances to the early days of recreational cannabis legalization in the U.S. In both cases, public enthusiasm and the rapid commercialization of products have significantly outpaced the development of robust regulatory frameworks necessary to safeguard public health. The cannabis industry, for example, quickly saw a proliferation of products with varying potencies and formulations, often before comprehensive testing standards or consumer safety guidelines were firmly established. This led to a period of trial and error, with consumers often lacking transparent information about product contents or potential risks.
Similarly, the expanding psilocybin market, characterized by increasing accessibility and product diversity, is moving faster than the scientific research and regulations required to ensure safe and informed use. Hollis Karoly, PhD, a clinical psychologist and neuroscientist, and Kent Hutchison, PhD, a professor of psychology and neuroscience, both seasoned substance use researchers with over a decade of experience studying high-THC cannabis products, highlight this critical gap. Their research aims to bridge the chasm between widespread public enthusiasm for psilocybin and the scarcity of scientific evidence regarding its real-world benefits and risks. Currently, comprehensive real-world data on the effects of psilocybin mushrooms – particularly those sourced from the burgeoning informal market – remains almost nonexistent. This knowledge vacuum poses significant challenges for policymakers, healthcare providers, and consumers alike.
The Intricacies of Psilocybin’s Mechanism
Understanding how psilocybin mushrooms exert their effects is crucial for both therapeutic development and risk mitigation. Psilocybin itself is a prodrug, meaning it has minimal activity until it is metabolized by the body into its active form, psilocin. Psilocin is the compound primarily responsible for the psychedelic experience. Chemically, psilocin bears a structural resemblance to serotonin, a vital neurotransmitter involved in a vast array of physiological and psychological functions, including mood regulation, appetite, cognition, and sensory perception. By binding to serotonin receptors, particularly the 5-HT2A receptor, psilocin profoundly alters an individual’s perception, thought processes, and emotional states.
Beyond its immediate psychoactive effects, emerging research suggests psilocin may also influence synaptic plasticity – the brain’s ability to strengthen or weaken neural connections. This profound alteration in neural connectivity is believed to underpin the sometimes long-lasting effects psilocybin can have on thoughts, emotions, and perception, contributing to its potential therapeutic benefits, such as breaking entrenched thought patterns in conditions like depression.
It is also important to note that psilocybin mushrooms are complex biological entities, containing numerous other compounds known as tryptamines, including baeocystin, norbaeocystin, and aeruginascin. Rodent studies indicate that mushrooms containing this full spectrum of compounds may elicit stronger and more prolonged effects compared to isolated psilocybin. However, federal regulations in the U.S. typically mandate the use of isolated, synthetic psilocybin in clinical research. This regulatory constraint means that the many ongoing clinical trials investigating psilocybin as a treatment for various mental health conditions utilize a purified compound, effectively sidelining research into the potential synergistic effects of the entire mushroom – often referred to as the "entourage effect" – and leaving a significant knowledge gap regarding how these other tryptamines affect human users.
A Patchwork of Legality: The Legal Gray Area
Despite federal prohibition, psilocybin has become more accessible than ever before, thanks to a decentralized movement towards decriminalization and legalization at the state and municipal levels. The turning point arrived in 2019 when Denver, Colorado, became the first American city to decriminalize psilocybin mushrooms. Decriminalization typically reduces or eliminates criminal penalties for possession, making it the lowest law enforcement priority, but it does not constitute full legalization.
In the subsequent two years, a wave of other U.S. cities followed Denver’s lead, including Oakland and Santa Cruz, California; Seattle, Washington; and Detroit, Michigan. These municipal actions reflected growing public and political will to re-evaluate the legal status of psychedelics. A more significant shift occurred in 2020 when Oregon became the first state to legalize psilocybin for supervised therapeutic use in licensed settings. Colorado followed suit in 2022, establishing similar regulated programs that allow access to psilocybin mushrooms without a prescription, provided use occurs within a supervised, licensed environment.
However, access to psilocybin is not limited to these specific jurisdictions. For individuals residing outside states and cities with decriminalization or legalization policies, barriers to access remain surprisingly low. A quick online search can yield kits containing mushroom spores, which are legally available for purchase and sale for around US$35. This legality stems from the fact that mushroom spores, being tiny reproductive cells, do not contain psilocybin themselves. However, once these spores begin to grow into mature mushrooms, they produce psilocybin, at which point the mushrooms become a Schedule I controlled substance under federal law. This legal loophole creates a "gray area" where cultivation is technically legal at the initial spore stage but becomes illegal once the psychoactive compound develops.
This complex and fragmented legal landscape means that psilocybin mushrooms are largely unregulated across most of the U.S. Consumers operating within this gray area lack crucial information about the contents and potency of their mushrooms, appropriate dosages, and best practices for safe use. This absence of regulation puts individuals at increased risk, as there are no mandated quality controls, labeling requirements, or age restrictions, leaving consumers vulnerable to potentially harmful products or practices.
The Rise of Potency and Product Diversity
Much like the evolution of the cannabis industry, which has seen a steady increase in product variety and strength since legalization, the psilocybin mushroom market is experiencing rapid growth and diversification. Psilocybin edibles, for instance, are becoming increasingly common and popular, appealing to consumers seeking alternative consumption methods to traditional dried mushrooms.
Furthermore, both individual growers and commercial cultivators are employing selective cultivation practices to systematically enhance the psilocybin content in their mushroom strains. Events like the Oakland Hyphae Cup, a community contest designed to identify superior mushroom strains, have revealed a wide variability in psilocybin content across different samples. This trend of increasing potency is mirrored in scientific studies globally, which consistently identify widely variable psilocybin content in psychedelic mushrooms. The lack of standardization and regulation in this burgeoning market means that consumers often have no way of knowing the actual dose they are consuming, increasing the risk of unintended and potentially harmful experiences.
Acknowledging Potential Harms
Despite the growing therapeutic promise of psilocybin, it is imperative to acknowledge and understand its associated risks. Common, albeit often mild, side effects can include headaches, nausea, dizziness, and fluctuations in blood pressure. More concerning, though less frequent, are psychological adverse reactions. Some individuals may experience acute psychotic symptoms, intense anxiety, paranoia, confusion, or severe emotional distress during or shortly after psilocybin use. In rare cases, individuals have reported suicidal thoughts, underscoring the importance of careful screening and supervised use, especially for those with pre-existing mental health vulnerabilities.
A particularly serious and persistent potential side effect associated with psychedelic drugs is Hallucinogen Persisting Perception Disorder (HPPD). HPPD involves ongoing perceptual distortions, such as visual snow, halos around objects, or intensified colors, which are similar to those experienced during acute psilocybin intoxication but can persist for weeks, months, or even years after the substance has left the body. While rare, HPPD can be highly distressing and debilitating.
The likelihood and severity of these harms are directly correlated with dosage. As the potency of unregulated psilocybin mushrooms continues to increase, consumers may inadvertently ingest significantly higher doses than intended, thereby escalating their risk of adverse effects. Without sufficient research into the composition and effects of modern psilocybin products available on the market, consumers lack adequate guidance on how to minimize potential harms. This knowledge deficit makes informed decision-making incredibly difficult and highlights the urgent need for comprehensive research and public health education campaigns.
The Urgent Need for Research and Regulation
Addressing the current regulatory vacuum and ensuring public safety requires innovative research approaches. Traditional clinical trials, while invaluable for establishing efficacy and safety under tightly controlled conditions with synthetic compounds, do not fully capture the real-world experiences of individuals using varied mushroom products in diverse, unsupervised settings.
Researchers like Karoly and Hutchison are advocating for creative research methodologies that can operate within existing federal restrictions. Their team, for example, hopes to study individuals using their own psilocybin mushroom products at home, collecting real-time data through app-based surveys. This approach would provide invaluable insights into actual usage patterns, experienced effects, and potential harms outside of a clinical environment.
To support such real-world studies and enhance consumer safety, independent laboratories equipped with state-of-the-art measurement techniques are critical. These labs can provide essential information about the potency and chemical composition of mushroom products, offering a vital layer of transparency and enabling researchers to correlate specific product characteristics with user experiences and outcomes.
The insights gleaned from both controlled clinical trials and real-world data are essential not only for scientists and policymakers but also for the burgeoning number of individuals turning to psilocybin mushrooms for relief from mental distress, self-improvement, or out of simple curiosity. In a largely unregulated market, where clear guidelines on safe use are scarce, consumers are currently left to navigate this complex landscape on their own, often without the necessary information or support. The federal government’s move to accelerate the review of psychedelics is a crucial step, but it must be accompanied by a concerted effort to establish comprehensive regulatory frameworks, fund robust real-world research, and implement effective public health education initiatives to ensure the responsible and safe integration of psilocybin into society.
Hollis Karoly, PhD, is a clinical psychologist, neuroscientist, and Associate Professor of Psychiatry at the University of Colorado Anschutz Medical Campus. Her research is funded by the National Institutes of Health.
Kent Hutchison, PhD, is a Professor of Psychology and Neuroscience at the University of Colorado in Boulder and the Founder of the Center for Research and Education Addressing Cannabis and Health. His research is also funded by the National Institutes of Health.
This article originally appeared in The Conversation and is republished with permission.